Caricamento...
Déjà vu: EGF receptors drive resistance to BRAF inhibitors
The promise of personalized medicine is upon us, and in some cancers targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but whereas drugs that targ...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3736320/ https://ncbi.nlm.nih.gov/pubmed/23658295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0131 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|